Kailera Therapeutics, Inc.
KLRAUnited States
2 filed reports · 158 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
2 reports · Mar 2026 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 2 | 332 | Mar 2026 to Jun 2026 |
Financial data
158 concepts · 332 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial158 concepts · 332 facts · Dec 2024 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value4 · Mar 2025 to Jun 2026
- Allocated share based compensation expense4 · Mar 2025 to Jun 2026
- Cash and cash equivalents at carrying value4 · Mar 2025 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents4 · Mar 2025 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations4 · Mar 2025 to Jun 2026
- Comprehensive income net of tax4 · Mar 2025 to Jun 2026
- Earnings per share basic4 · Mar 2025 to Jun 2026
- Earnings per share diluted4 · Mar 2025 to Jun 2026
- General and administrative expense (US GAAP)4 · Mar 2025 to Jun 2026
- Interest income expense nonoperating net4 · Mar 2025 to Jun 2026
- Lease cost4 · Mar 2025 to Jun 2026
- Net income loss4 · Mar 2025 to Jun 2026
- Operating expenses (US GAAP)4 · Mar 2025 to Jun 2026
- Operating income loss4 · Mar 2025 to Jun 2026
- Operating lease cost4 · Mar 2025 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax4 · Mar 2025 to Jun 2026
- Other nonoperating income expense4 · Mar 2025 to Jun 2026
- Research and development expense4 · Mar 2025 to Jun 2026
- Restricted cash and cash equivalents4 · Mar 2025 to Jun 2026
- Share based compensation arrangement by share based payment award fair value assumptions expected dividend rate4 · Mar 2025 to Jun 2026
- Share based compensation arrangement by share based payment award fair value assumptions expected volatility rate4 · Mar 2025 to Jun 2026
- Share based compensation arrangement by share based payment award fair value assumptions risk free interest rate4 · Mar 2025 to Jun 2026
- Stockholders equity (US GAAP)4 · Mar 2025 to Jun 2026
- Variable lease cost4 · Mar 2025 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.